Povorcitinib

Povorcitinib
Clinical data
Other names	INCB-054707
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide;
CAS Number	1637677-22-5 ;
PubChem CID	86280672 ;
IUPHAR/BPS	11881 ;
DrugBank	DB18855 ;
ChemSpider	115010428 ;
UNII	N0JWC7RO00 ;
KEGG	D12575 ;
ChEMBL	ChEMBL5095079 ;
Chemical and physical data
Formula	C23H22F5N7O
Molar mass	507.469 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N[C@@H](C)C(F)(F)F)F)CC#N;
	InChI InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1; Key:MSGYSFWCPOBHEV-AWEZNQCLSA-N;

Last updated June 30, 2025

Povorcitinib is an investigational new drug that is being evaluated for the treatment of the skin conditions hidradenitis suppurativa ^[1]^[2] and chronic prurigo.^[3]^[4] It is a JAK1 inhibitor.^[5]

References

↑ Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, et al. (May 2022). "Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies". The British Journal of Dermatology. 186 (5): 803–813. doi:10.1111/bjd.20969. PMC 9314604 . PMID 34978076.
↑ Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, et al. (March 2024). "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study". Journal of the American Academy of Dermatology. 90 (3): 521–529. doi: 10.1016/j.jaad.2023.10.034 . PMID 37871805.
↑ "Povorcitinib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.
↑ Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C (June 2024). "Chronic Prurigo". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. 22 (6): 813–823. doi: 10.1111/ddg.15317 . PMID 38722190.
↑ Liao V, Cornman HL, Ma E, Kwatra SG (May 2024). "Prurigo nodularis: new insights into pathogenesis and novel therapeutics". The British Journal of Dermatology. 190 (6): 798–810. doi:10.1093/bjd/ljae052. PMC 11099982 . PMID 38345154.

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, et al. (May 2022). "Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies". The British Journal of Dermatology. 186 (5): 803–813. doi:10.1111/bjd.20969. PMC 9314604 . PMID 34978076.

[2] Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, et al. (March 2024). "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study". Journal of the American Academy of Dermatology. 90 (3): 521–529. doi: 10.1016/j.jaad.2023.10.034 . PMID 37871805.

[3] "Povorcitinib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.

[pmid38722190-4] Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C (June 2024). "Chronic Prurigo". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. 22 (6): 813–823. doi: 10.1111/ddg.15317 . PMID 38722190.

[Liao_2024-5] Liao V, Cornman HL, Ma E, Kwatra SG (May 2024). "Prurigo nodularis: new insights into pathogenesis and novel therapeutics". The British Journal of Dermatology. 190 (6): 798–810. doi:10.1093/bjd/ljae052. PMC 11099982 . PMID 38345154.

[1]

[2]

[3]

[4]

[5]